Andrea Doak
Medical · Augusta, GANPI 1760420202
Payments from drug & device makers
Across 291 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Esperion Therapeutics, Inc.$567
- AbbVie$564
- Bayer$561
- Novo Nordisk$547
- plus $2K from 22 others
What the payments were for
- Food & beverage$7,394100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 67 | $2,088 |
| GSK | 56 | $1,420 |
| Esperion Therapeutics, Inc. | 15 | $567 |
| AbbVie | 41 | $564 |
| Bayer | 14 | $561 |
| Novo Nordisk | 28 | $547 |
| Lilly USA, LLC | 19 | $483 |
| Dexcom, Inc. | 6 | $214 |
| Amgen(2 entities) | 11 | $149 |
| Organogenesis Inc. | 1 | $125 |
| Veloxis Pharmaceuticals, Inc. | 1 | $98 |
| Sanofi | 5 | $83 |
| Amarin Pharma, Inc. | 5 | $79 |
| Mylan Specialty L.p. | 4 | $68 |
| Bolton Medical Inc | 1 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Boehringer Ingelheim | 2 | $33 |
| Merck | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Novartis | 1 | $23 |
| Advanced Respiratory, Inc | 1 | $22 |
| Pfizer | 1 | $20 |
| Stryker | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $20 |
| Inogen, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,405 in reported general payments places this provider in the 85th percentile of 950 medical providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 121 | $176,501 |
| FarxigaDapagliflozin Propanediol | 88 | $102,997 |
| OzempicSemaglutide | 39 | $78,010 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $78,004 |
| KerendiaFinerenone | 38 | $40,302 |
| EliquisApixaban | 23 | $28,125 |
| JardianceEmpagliflozin | 14 | $26,368 |
| JanuviaSitagliptin Phosphate | 22 | $18,955 |
| RybelsusSemaglutide | 13 | $15,888 |
| XareltoRivaroxaban | 12 | $14,168 |
| Repatha SureclickEvolocumab | 16 | $12,005 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $11,481 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 172 | $9,056 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $8,099 |
| Ventolin HfaAlbuterol Sulfate | 41 | $4,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $483 | $176,501121 claims |
| AstraZenecaFarxiga | $2,088 | $102,99788 claims |
| Novo NordiskOzempic, Rybelsus | $547 | $93,89852 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,420 | $89,486121 claims |
| BayerKerendia | $561 | $40,30238 claims |
| PfizerEliquis | $20 | $28,12523 claims |
| Boehringer IngelheimJardiance | $33 | $26,36814 claims |
| MerckJanuvia | $32 | $18,95522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 950 medical providers in Georgia.
Other medical in Augusta
- Derek LafontAugusta$24K
- Keifer RichardsonAugusta$14K
- Tomas ChaoWoodstock$1.9M
- Kimberly OrleckAtlanta$727K
- Audrey GibsonGainesville$302K
- Lisa WeissCanton$283K
- Laura BushFayetteville$146K
- Michael KelleherMarietta$126K
- Juliena GigonMarietta$122K
- Felicia HoffmanRoswell$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.